Amiloride discontinuation leaves gap in treatment of aldosteronism

Cardiologists are mounting a campaign to restore access to the diuretic amiloride, saying its sudden discontinuation has left a gap in treatment options for patients with primary aldosteronism. The potassium-sparing diuretic was taken off the market on March 12 by Alphapharm due to manufacturing issues, according to a notification by the Therapeutic Goods Administration (TGA). ...

Already a member?

Login to keep reading.

© 2021 the limbic